Systemic Janus Kinase Inhibitor Treatment for Vitiligo: An Evidence-Based Review
Published: 10 September 2024| Version 1 | DOI: 10.17632/3d7pr7673v.1
Contributor:
Siddhartha SoodDescription
Vitiligo is an immune-mediated condition characterized by melanocyte loss. While topical Janus kinase inhibitors (JAKi) have recently been FDA-approved for refractory nonsegmental vitiligo, use of systemic JAKi remains novel. This systematic review summarizes evidence regarding this indication.
Files
Categories
Dermatology